Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Aim(s): To assess the potential prognostic impact of MET administered during EVE therapy among DM pts with advanced NETs.
Materials and methods: We retrospectively identified pts with advanced G1-G2 gastroenteropancreatic and lung NETs treated with EVE at 7 Spanish University hospitals. Cox proportional hazard models controlling for primary tumour site, grade and previous therapies were used to compare progression-free survival (PFS) across non-DM pts, DM pts on MET and DM pts on anti-DM agents other than MET.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
, Jiménez-Fonseca P
, Alonso-Orduña V
, López López C
, Alonso T
, Crespo G
, Carmona-Bayonas A
, Álvarez-Escolá C
, Solís M P
, Capdevila J
, Feliu J
, Aller J
, Grande E
, Barriuso J
To read results and conclusion, please login ...
Further abstracts you may be interested in